meta|evidence oncology

Living systematic review and meta-analysis

metastatic, hormone-sensitive prostate cancer 11
renal cell cancer (RCC)

immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
atezolizumab plus bevacizumab
atezolizumab plus cabozantinib
avelumab based treatment
avelumab plus axitinib
nivolumab based treatment
nivolumab alone
nivolumab plus cabozantinib
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab plus axitinib
pembrolizumab plus lenvatinib
Immune checkpoint association
nivolumab plus ipilimumab
mTOR inhibitors
everolimus
lenvatinib plus everolimus
VEGF(R) inhibitor
lenvatinib
lenvatinib in association

versus all
vs immune chekpoint inhibitors
vs Immune checkpoint association
vs nivolumab plus ipilimumab
vs mTOR inhibitors
vs everolimus
vs non active control
vs placebo
vs VEGF(R) inhibitor
vs cabozantinib
vs sunitinib

study list
mapping
overview
meta-analysis
forest plot
NMA
excluded

Study		Exclusion reasons	Remarks	Reference(s)
KEYNOTE-B61, 2023	randomized controlled trial	inadequate or absent control group		Albiges L Lancet Oncology july 2023 10.1016/S1470-2045(23)00276-0

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -